Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations.
Alfred SackeyfioRenato D LopesCsaba Pal KovesdyAleix CasesSteve A MallettNick BallewTom J KeeleyViviana Garcia-HortonRajeev AyyagariRodrigo Refoios CamejoKirsten L JohansenAlexander J SuttonIndranil DasguptaPublished in: Clinical kidney journal (2023)
In the setting of anaemia in CKD, indirect treatment comparisons suggest that daprodustat, roxadustat, and vadadustat are broadly clinically comparable in terms of efficacy and cardiovascular safety (precision was low for the latter), while daprodustat may be associated with reduction in fatigue to a greater extent than roxadustat.